-DOCSTART- -X- O
Feline -X- _ B-Patient
Chronic -X- _ I-Patient
Gingivostomatitis -X- _ I-Patient
Syndrome -X- _ I-Patient
( -X- _ I-Patient
FCGS -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
a -X- _ O
common -X- _ O
disease -X- _ O
in -X- _ O
clinical -X- _ O
practice. -X- _ O
Among -X- _ O
the -X- _ O
therapeutic -X- _ O
options -X- _ O
available -X- _ O
, -X- _ O
long-acting -X- _ O
corticosteroids -X- _ O
are -X- _ O
frequently -X- _ O
used -X- _ O
due -X- _ O
to -X- _ O
their -X- _ O
anti-inflammatory -X- _ O
and -X- _ O
immunosuppressive -X- _ O
properties. -X- _ O
Although -X- _ O
they -X- _ O
may -X- _ O
improve -X- _ O
the -X- _ O
clinical -X- _ O
symptoms -X- _ O
, -X- _ O
they -X- _ O
can -X- _ O
lead -X- _ O
to -X- _ O
a -X- _ O
progressive -X- _ O
form -X- _ O
of -X- _ O
the -X- _ O
disease -X- _ O
that -X- _ O
becomes -X- _ O
refractory -X- _ O
to -X- _ O
treatment. -X- _ O
Furthermore -X- _ O
, -X- _ O
their -X- _ O
direct -X- _ O
relationship -X- _ O
with -X- _ O
type -X- _ B-Patient
II -X- _ I-Patient
diabetes -X- _ I-Patient
mellitus -X- _ I-Patient
( -X- _ I-Patient
DM -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
well -X- _ O
known. -X- _ O
Consequently -X- _ O
, -X- _ O
these -X- _ O
drugs -X- _ O
are -X- _ O
controversial -X- _ O
and -X- _ O
not -X- _ O
recommended -X- _ O
for -X- _ O
routine -X- _ O
management -X- _ O
of -X- _ O
FCGS. -X- _ B-Patient
Recombinant -X- _ B-Intervention
feline -X- _ I-Intervention
interferon-omega -X- _ I-Intervention
( -X- _ I-Intervention
rFeIFN-ω -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
an -X- _ O
immunomodulatory -X- _ O
compound. -X- _ O
Recently -X- _ O
, -X- _ O
its -X- _ O
daily -X- _ B-Intervention
oral -X- _ I-Intervention
administration -X- _ I-Intervention
has -X- _ O
been -X- _ O
shown -X- _ O
to -X- _ O
be -X- _ O
successful -X- _ O
in -X- _ O
treating -X- _ O
refractory -X- _ B-Patient
cases -X- _ I-Patient
of -X- _ I-Patient
FCGS. -X- _ I-Patient
This -X- _ O
case -X- _ O
study -X- _ O
describes -X- _ O
two -X- _ O
clinical -X- _ O
cases -X- _ O
of -X- _ O
type -X- _ B-Patient
II -X- _ I-Patient
DM -X- _ I-Patient
complicated -X- _ I-Patient
by -X- _ I-Patient
FCGS. -X- _ I-Patient
Both -X- _ O
animals -X- _ O
were -X- _ O
calicivirus -X- _ O
positive -X- _ O
and -X- _ O
they -X- _ O
had -X- _ O
been -X- _ O
previously -X- _ O
treated -X- _ O
with -X- _ O
long-acting -X- _ O
corticosteroids -X- _ O
, -X- _ O
which -X- _ O
may -X- _ O
have -X- _ O
been -X- _ O
the -X- _ O
major -X- _ O
cause -X- _ O
of -X- _ O
DM. -X- _ O
The -X- _ O
two -X- _ B-Patient
cats -X- _ I-Patient
were -X- _ O
treated -X- _ O
with -X- _ O
glargine -X- _ O
insulin -X- _ O
( -X- _ O
Lantus -X- _ O
, -X- _ O
starting -X- _ O
dose -X- _ O
1 -X- _ O
IU -X- _ O
/ -X- _ O
cat -X- _ O
twice -X- _ O
daily -X- _ O
( -X- _ O
BID -X- _ O
) -X- _ O
) -X- _ O
, -X- _ O
achieving -X- _ O
remission -X- _ O
10 -X- _ O
and -X- _ O
18 -X- _ O
weeks -X- _ O
later -X- _ O
respectively. -X- _ O
Considering -X- _ O
the -X- _ O
difficulty -X- _ O
with -X- _ O
control -X- _ O
of -X- _ O
FCGS -X- _ O
in -X- _ O
these -X- _ O
animals -X- _ O
, -X- _ O
an -X- _ O
oral -X- _ B-Intervention
daily -X- _ I-Intervention
dose -X- _ I-Intervention
of -X- _ I-Intervention
rFeIFN-ω -X- _ I-Intervention
was -X- _ O
started -X- _ O
as -X- _ O
an -X- _ O
alternative -X- _ O
to -X- _ O
long-acting -X- _ O
corticosteroids. -X- _ O
In -X- _ B-Outcome
both -X- _ I-Outcome
cats -X- _ I-Outcome
oral -X- _ I-Outcome
clinical -X- _ I-Outcome
signs -X- _ I-Outcome
gradually -X- _ I-Outcome
improved -X- _ I-Outcome
and -X- _ I-Outcome
60 -X- _ I-Outcome
days -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
start -X- _ I-Outcome
of -X- _ I-Outcome
therapy -X- _ I-Outcome
the -X- _ I-Outcome
owners -X- _ I-Outcome
reported -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
relief -X- _ I-Outcome
of -X- _ I-Outcome
pain -X- _ I-Outcome
during -X- _ I-Outcome
mastication. -X- _ I-Outcome
According -X- _ O
to -X- _ O
the -X- _ O
authors’ -X- _ O
knowledge -X- _ O
, -X- _ O
this -X- _ O
is -X- _ O
the -X- _ O
first -X- _ O
case -X- _ O
report -X- _ O
that -X- _ O
describes -X- _ O
the -X- _ O
successful -X- _ B-Outcome
use -X- _ I-Outcome
of -X- _ I-Outcome
rFeIFN-ω -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
management -X- _ I-Outcome
of -X- _ I-Outcome
FCGS -X- _ I-Outcome
in -X- _ I-Outcome
type -X- _ I-Outcome
II -X- _ I-Outcome
diabetic -X- _ I-Outcome
cats -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
which -X- _ I-Outcome
long-acting -X- _ I-Outcome
corticosteroids -X- _ I-Outcome
are -X- _ I-Outcome
contraindicated -X- _ I-Outcome
. -X- _ O

